Renal Cell Carcinoma Clinical Trial
Official title:
T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY)
To define the frequency of T regulatory cells in peripheral blood of RCC patients before and
after nephrectomy.
Study hypothesis: That nephrectomy results in a normalisation of peripheral blood T regs in
early stage RCC, and a lowering of T regs in advanced RCC.
T regulatory cells (T regs) are a recently identified subset of T cells with inhibitory
functions on the immune system. In cancer, it has been shown that there is an increased
proportion of T regs in several different human malignancy states. T regs are found to be
elevated in peripheral blood mononuclear cells, draining lymph nodes and in the primary
tumor itself. There has also been correlation between peripheral blood T regs and tumor
stage, tumor relapse and survival. It has been proposed that the T regs are activated and
expanded by factors produced by the tumor microenvironment. They are thought to play a role
in preventing or demising host T-cell responses against cancer, including a suboptimal host
responses to vaccine strategies. Strategies to reduce T regs in cancer patients are being
explored as a novel immunologic anti-cancer approach.
Renal cell cancer (RCC) is a tumor with well-known immune-mediated phenomena such as
spontaneous regression. There is paucity of data on T regs in RCC. We propose to study the
frequency of peripheral blood T regs before and after nephrectomy for RCC. We will document
the baseline frequency of T regs in RCC and if nephrectomy results in a change in levels. We
hypothesize that nephrectomy will lower peripheral T regs to normal levels in early stage
RCC, and will reduce peripheral T reg levels in advanced RCC patients. If found to be so, T
regs could in future be used as an indicator of disease recurrence in early stage RCC. In
advanced RCC, lowering of T reg levels may help explain the previous hypothesis that
debulking nephrectomy results in improved anti-tumor immunity, provide rationale for second
debulking procedures, and be correlated with subsequent clinical course.
The main laboratory technique is flow cytometry. This will be a pilot study with small
patient numbers. Only blood samples are required.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04987203 -
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Completed |
NCT02853344 -
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
|
Phase 2 | |
Terminated |
NCT04088500 -
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05070637 -
Circulating Tumor Cell Reducing No-touch Nephrectomy
|
N/A | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Not yet recruiting |
NCT06049030 -
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01358721 -
Phase I Biomarker Study (BMS-936558)
|
Phase 1 | |
Active, not recruiting |
NCT04503148 -
Anesthesia and Cancer Study: Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Not yet recruiting |
NCT05808608 -
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03323710 -
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT03052504 -
Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy
|